Health Review Macao: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Review Macao.

Press releases published on May 19, 2026

May 19, 2026

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

Indeterminate GlobeNewswire

May 19, 2026

Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences

Indeterminate GlobeNewswire

May 19, 2026

Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease

Indeterminate GlobeNewswire

May 19, 2026

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Indeterminate GlobeNewswire

May 19, 2026

EyePoint Announces Participation at Upcoming Investor Conferences

Indeterminate GlobeNewswire

May 19, 2026

XORTX Announces Closing of US$5 Million Public Offering

Indeterminate GlobeNewswire

May 19, 2026

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Indeterminate GlobeNewswire

May 19, 2026

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Indeterminate GlobeNewswire

May 19, 2026

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Indeterminate GlobeNewswire

May 19, 2026

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

Indeterminate GlobeNewswire

May 19, 2026

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Indeterminate GlobeNewswire

May 19, 2026

Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand

Indeterminate GlobeNewswire

May 19, 2026

EuroPCR 2026: DynamX® Bioadaptor von Elixir Medical zeigt in der Langzeit-Nachbeobachtung signifikant niedrigere Ereignisraten als ein medikamentenfreisetzender Stent

Indeterminate GlobeNewswire

May 19, 2026

EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent

Indeterminate GlobeNewswire

May 19, 2026

El bioadaptador DynamX® de Elixir Medical demuestra tasas de acontecimientos significativamente inferiores a las de los stents liberadores de fármacos

Indeterminate GlobeNewswire

May 19, 2026

Le Bioadaptateur DynamX® d’Elixir Medical démontre une réduction significative des taux d’événements coronariens par rapport à un stent à élution médicamenteuse

Indeterminate GlobeNewswire

May 19, 2026

EuroPCR 2026: DynamX® Bioadaptor di Elixir Medical mostra tassi di eventi significativamente inferiori rispetto allo stent a rilascio di farmaco

Indeterminate GlobeNewswire

May 19, 2026

EuroPCR 2026: Bioadaptator DynamX® firmy Elixir Medical wykazuje istotne obniżenie występowania zdarzeń niepożądanych

Indeterminate GlobeNewswire

May 19, 2026

Avance Clinical to Showcase Oncology Leadership at ASCO Annual Meeting 2026

Indeterminate GlobeNewswire

May 19, 2026

Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results

Indeterminate GlobeNewswire